Conexeu Sciences Inc.

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

Conexeu Sciences reported that multiple scaled-up batches of its CXU material met predefined specifications, a key step in moving Ten Minute Tissue from development toward commercial manufacturing. The company reaffirmed that its FDA 510(k) submission for the lead wound care device remains on track for the first quarter of 2027, supported by preclinical, biocompatibility, and sterilization workstreams plus prior FDA Q-Submission feedback. The update is positive but incremental; the device remains investigational, all cited evidence is preclinical, and 510(k) clearance is not assured.

•19d ago

The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.

A paid commentary distributed by American News Group references AMD as an example of a company that successfully redefined its market category, transitioning from a value processor alternative to a central supplier of AI infrastructure. The article notes that AMD reported record quarterly revenue in 2026 and saw significant share price growth due to data-center demand, though it provides no specific financial figures. This release is a sponsored advertisement for Conexeu Sciences Inc. and does not originate from AMD or contain new material information regarding the company.

•2mo ago

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Conexeu Sciences completed the 12-month P.R.O.O.F. phase of its CXU preclinical program, successfully meeting predefined objectives in both small-volume facial and large-volume subcutaneous tissue models. The company highlighted third-party research estimating the regenerative aesthetics market at $15.6 billion in 2025, with the bioregenerative injectables segment projected to grow at over 11% annually. Management is targeting a 510(k) submission in early 2027 for its lead device candidate, Ten-Minute Tissue™, which aims to address soft tissue restoration following aging or weight loss.

•2mo ago

Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

Conexeu's Chief Medical Officer Dr. Brian Pilcher will present at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium on August 15, 2026. The presentation will focus on the extracellular matrix and its role in tissue regeneration, highlighting ECM-based approaches for regenerative aesthetics. The company remains preclinical, with an anticipated 510(k) submission for its lead device candidate, Ten-Minute Tissue, expected in early 2027.

•2mo ago

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Conexeu Sciences announced the completion of its 12-month preclinical P.R.O.O.F. study evaluating the CXU™ tissue-restoration platform for large-volume body contouring. The company targets a $2 billion aesthetic opportunity driven by GLP-1 weight loss and plans to submit a 510(k) application for its lead candidate in the first quarter of 2027. Management highlighted that existing injectables are unsuited for the high volumes required for body contouring, positioning CXU™ as a potential first-mover in the bioregeneration category.

•3mo ago

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill

Conexeu Sciences announced the completion of its P.R.O.O.F preclinical program, demonstrating that its CXU platform met objectives for tissue restoration and injectable performance benchmarks in animal models. The company positions its technology to address the tissue-restoration gap created by GLP-1 weight-loss drugs, citing a projected market expansion from $0.7 billion to $2.0 billion by 2030 for related aesthetic procedures. Management plans a predicate-based 510(k) submission for wound care in Q1 2027, targeting a 90-day FDA review as a foundational step toward expanding into medical aesthetics.

•3mo ago

The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real · and a Newly Public Regenerative Player Wants to Compete for It

A paid market commentary article highlights the growing trend of treating facial volume loss caused by GLP-1 weight-loss drugs, citing AbbVie's Allergan Aesthetics division as a key large-cap anchor in the space. The article notes that AbbVie's medical-affairs leadership is actively co-authoring clinical literature on treating GLP-1 aesthetic patients, validating the market opportunity alongside peers like Galderma, Establishment Labs, and InMode. While the primary focus of the advertisement is the newly public company Conexeu Sciences, the analysis frames the expanding GLP-1 aesthetics category as a significant demand driver for established industry players.

•4mo ago

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences opened a new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver to support its regenerative tissue platform. The 30,000-square-foot hub provides specialized laboratory infrastructure for the company's ongoing research and product development efforts, including the CXU™ platform and B.R.E.A.S.T.™ matrix. Management anticipates submitting a 510(k) application for its lead device candidate, Ten-Minute Tissue™, in early 2027, targeting multi-billion-dollar markets in wound care and body contouring.

•4mo ago

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

Conexeu Sciences reports transferring standardized formulation methods to its CDMO and advancing manufacturing scale-up activities for its lead wound-care device candidate. The company is preparing a 510(k) premarket notification targeted for the first quarter of 2027, supported by prior FDA pre-submission feedback through the Q-Submission process. Development of the CXU™ platform includes a preclinical breast matrix program in collaboration with Wake Forest Institute for Regenerative Medicine, targeting broader applications beyond wound care.

•4mo ago

A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

Conexeu Sciences is advancing its lead CXU wound-care program into manufacturing scale-up and regulatory preparation, targeting a 510(k) submission in Q1 2027. The company has transferred standardized formulation methods to a CDMO and is producing representative materials for analytical, biocompatibility, and sterilization testing. This operational progress marks a transition from research-stage development to regulatory-execution activities, supported by prior FDA pre-submission feedback.

•4mo ago

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Conexeu Sciences announced progress in manufacturing scale-up and standardized formulation methods for its lead CXU™ wound care device candidate with its CDMO. The company is advancing activities to support a planned 510(k) premarket notification submission to the FDA during the first quarter of 2027. Management highlighted that the program is transitioning from research-stage development into manufacturing, testing, and regulatory execution, having received advisory pre-submission feedback from the FDA.

•4mo ago

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu Sciences has launched a preclinical development program for its B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine (WFIRM). The study will evaluate the durability, host tissue integration, and resorbability of the proprietary CXU™ matrix, leveraging WFIRM’s advanced bioprinting infrastructure. Results from this preclinical work will inform future study designs and guide progression toward clinical development, with a 510(k) submission targeted for early 2027.

•4mo ago

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Conexeu Sciences (CNXU) announced a preclinical development partnership with the Wake Forest Institute for Regenerative Medicine (WFIRM) to evaluate its proprietary B.R.E.A.S.T. 3D-printed tissue matrix. The program will leverage WFIRM’s Integrated Tissue-Organ Printing System (iTOPS) to assess durability, host tissue integration, and resorbability of the matrix, aiming to generate data for future clinical investigation. Conexeu, which commenced trading on Nasdaq on May 21, 2026, targets a 510(k) regulatory submission in early 2027 for its initial indication, positioning its CXU platform against established competitors in breast reconstruction and regenerative medicine.

•4mo ago